TETRA BIO-PHARMA INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | 0.00% |
|
0.00% | -99.83% |
Valuation
| Fiscal Period: november | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 22.53 | 82.71 | 169.8 | 80.13 | 54.01 | 88.81 |
| Enterprise Value (EV) 1 | 21.31 | 80.51 | 156.2 | 78.09 | 53.51 | 87.03 |
| P/E ratio | -19 x | -12.1 x | -20.1 x | -4.64 x | -1.86 x | -1.7 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 1,511,706,942 x | - | - | - |
| EV / Revenue | - | - | 1,390,751,877 x | - | - | - |
| EV / EBITDA | - | -12,066,992 x | -13,105,856 x | -5,492,144 x | -2,616,197 x | -3,625,777 x |
| EV / FCF | -37.5 x | -30.8 x | -33.8 x | -7.86 x | -4.75 x | -5.18 x |
| FCF Yield | -2.67% | -3.25% | -2.96% | -12.7% | -21% | -19.3% |
| Price to Book | 16.2 x | 7.72 x | 8.13 x | 3.25 x | 2.39 x | 357 x |
| Nbr of stocks (in thousands) | 81,460 | 118,791 | 162,832 | 212,839 | 283,827 | 401,667 |
| Reference price 2 | 0.2766 | 0.6962 | 1.043 | 0.3765 | 0.1903 | 0.2211 |
| Announcement Date | 3/27/17 | 4/2/18 | 3/15/19 | 3/25/20 | 2/17/21 | 2/28/22 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: november | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net sales | - | - | 0.1123 | - | - | - |
| EBITDA | - | -6.672 | -11.92 | -14.22 | -20.45 | -24 |
| EBIT 1 | -0.9966 | -6.68 | -11.93 | -14.25 | -20.49 | -24.12 |
| Operating Margin | - | - | -10,618.09% | - | - | - |
| Earnings before Tax (EBT) 1 | -0.997 | -6.695 | -7.852 | -14.25 | -21.15 | -52.18 |
| Net income 1 | -0.9443 | -6.225 | -7.573 | -15.28 | -26.48 | -52.18 |
| Net margin | - | - | -6,741.95% | - | - | - |
| EPS 2 | -0.0146 | -0.0578 | -0.0520 | -0.0812 | -0.1026 | -0.1299 |
| Free Cash Flow 1 | -0.5683 | -2.615 | -4.618 | -9.931 | -11.26 | -16.79 |
| FCF margin | - | - | -4,111.82% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/27/17 | 4/2/18 | 3/15/19 | 3/25/20 | 2/17/21 | 2/28/22 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: November | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 1.22 | 2.19 | 13.6 | 2.04 | 0.5 | 1.77 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -0.57 | -2.62 | -4.62 | -9.93 | -11.3 | -16.8 |
| ROE (net income / shareholders' equity) | -171% | -111% | -49.8% | -62.6% | -89.6% | -457% |
| ROA (Net income/ Total Assets) | -76.5% | -65.6% | -43.1% | -34.2% | -44.2% | -81.7% |
| Assets 1 | 1.234 | 9.489 | 17.56 | 44.63 | 59.86 | 63.85 |
| Book Value Per Share 2 | 0.0200 | 0.0900 | 0.1300 | 0.1200 | 0.0800 | 0 |
| Cash Flow per Share 2 | 0.0100 | 0.0200 | 0.0800 | 0.0100 | 0.0100 | 0.0100 |
| Capex | - | - | - | 0.25 | 0.24 | 0.34 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/27/17 | 4/2/18 | 3/15/19 | 3/25/20 | 2/17/21 | 2/28/22 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -99.83% | 515 | |
| +40.09% | 6.3B | |
| -16.34% | 4.53B | |
| -7.11% | 3.29B | |
| +5.14% | 3.2B | |
| -0.18% | 2.63B | |
| +47.93% | 1.97B | |
| -7.15% | 1.74B | |
| +0.67% | 1.69B | |
| -8.73% | 1.64B |
- Stock Market
- Equities
- TBPMQ Stock
- Financials Tetra Bio-Pharma Inc.
